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Abstract
Background: RNA interference (RNAi) has proven to be a powerful tool to suppress gene
expression and can be used as a therapeutic strategy against human pathogenic viruses such as
human immunodeficiency virus type 1 (HIV-1). Theoretically, RNAi-mediated inhibition can occur
at two points in the replication cycle, upon viral entry before reverse transcription of the RNA
genome, and on the newly transcribed viral RNA transcripts. There have been conflicting results
on whether RNAi can target the RNA genome of infecting HIV-1 particles. We have addressed this
issue with HIV-1-based lentiviral vectors.
Results: We determined the transduction efficiency of a lentiviral vector, as measured by GFP
expressing cells, which reflects the number of successful integration events in a cell line stably
expressing shNef. We did not observe a difference in the transduction efficiency comparing
lentiviral vectors with or without the Nef target sequence in their genome. The results were similar
with particles pseudotyped with either the VSV-G or HIV-1 envelope. Additionally, no reduced
transduction efficiencies were observed with multiple other shRNAs targeting the vector genome
or with synthetic siNef when transiently transfected prior to transduction.
Conclusion: Our findings indicate that the incoming HIV-1 RNA genome is not targeted by RNAi,
probably due to inaccessibility to the RNAi machinery. Thus, therapeutic RNAi strategies aimed at
preventing proviral integration should be targeting cellular receptors or co-factors involved in pre-
integration events.
Background
Double stranded RNA (dsRNA) can induce RNA interfer-
ence (RNAi) in cells, resulting in sequence-specific degra-
dation of the targeted mRNA [1,2]. Short interfering RNAs
(siRNAs) of ~22 nt are the effector molecules of this evo-
lutionarily conserved mechanism and are produced by a
ribonuclease named Dicer [3,4]. One strand of the siRNA
duplex is incorporated into the RNA-induced silencing
complex (RISC), which binds to and cleaves complemen-
tary RNA sequences [5,6]. RNAi has proven to be a power-
ful tool to suppress gene expression. Transfection of
synthetic siRNA into cells results in transient inhibition of
the targeted gene [7]. Stable gene suppression can be
achieved by the introduction of vectors that express siR-
NAs or short hairpin RNAs (shRNAs) that are processed
into siRNAs by Dicer [8,9].
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RNAi can be used as a therapeutic strategy against human
pathogenic viruses such as HIV-1 [10]. Several studies
have demonstrated that HIV-1 replication can be inhib-
ited transiently by transfection of synthetic siRNAs target-
ing either viral RNA sequences or cellular mRNAs
encoding protein co-factors that support HIV-1 replica-
tion [11-20]. Furthermore, several groups have demon-
strated long-term inhibition of HIV-1 replication in
transduced cell lines that stably express an antiviral siRNA
or shRNA [21-28]. However, HIV-1 escape variants with
nucleotide substitutions or deletions in the siRNA target
sequence emerge after prolonged culturing [22,24]. We
have also demonstrated that HIV-1 can gain resistance
against RNAi through mutations that mask the target in a
stable RNA secondary structure [29]. The use of combina-
tion-shRNA therapy, in which multiple conserved viral
RNA sequences are targeted by multiple shRNAs at the
same time, may block the emergence of RNAi resistant
variants [30].
During the HIV-1 life cycle, there are two phases that
could potentially be targeted by RNAi [31,32]. Newly
made viral transcripts, synthesized from the integrated
proviral DNA, are the obvious targets. In addition, RNAi
may target the virion-associated or "incoming" viral RNA
genome during the initial phase of infection prior to com-
pletion of reverse transcription that converts the RNA
genome into DNA. During the infection, the HIV-1 core
particle traverses through the cytoplasm, where the RNAi
machinery resides. If the RNA genome within the virion
core is accessible to the RISC complex, reverse transcrip-
tion and subsequent proviral integration would be
blocked, which is highly desirable in a therapeutic setting.
There have been conflicting results on whether RNAi can
target the RNA genome of infecting HIV-1 particles. Sev-
eral groups have reported degradation of the incoming
RNA genome in cells transfected with siRNAs [11,12,16].
Recently, a study showed inhibition of HIV-1 provirus
integration in cells stably expressing shRNAs at a low virus
input [33]. Other publications report no RNAi-mediated
degradation of the RNA genome in siRNA-transfected or
shRNA-producing cells [17,18,34]. In the present study,
we have readdressed the issue of incoming HIV-1 genome
targeting using HIV-1-based lentiviral vectors in which we
used transduction as a model for proviral integration. Tar-
geting of the incoming genome did not reduce the trans-
duction efficiency, indicating that the HIV-1 RNA genome
is not a target for RNAi during the initial phase of infec-
tion.
Results
To determine the amount of incoming HIV-1 RNA in cells
expressing antiviral siRNAs, the integrated HIV-1 DNA
product or pre-integration DNA intermediates have been
quantified [12,16-18,33,34]. Instead, we use an HIV-1
based lentiviral vector system to study proviral integration
in cells expressing shRNAs against the HIV-1 lentiviral vec-
tor genome. We chose the lentiviral vector system because
it is ideally suited to study proviral integration since viral
infection is limited to a single cycle and is easily scored
with FACS analysis detecting reporter gene expression in
transduced cells. JS1 is a third generation self-inactivating
lentiviral vector containing a GFP reporter gene (Fig. 1).
Lentiviral vector particles are produced in 293T cells by
co-transfection of the vector plasmid with the packaging
constructs encoding Gag-Pol, Rev, and the VSV-G enve-
lope protein (Fig. 1). Transduction titers of the produced
lentiviral vectors were determined. All infection experi-
ments were subsequently carried out at relatively low mul-
tiplicity of infection (m.o.i) such that transduced cells
were preferably infected by a single vector. Thus, a trans-
duced cell represents a single successful reverse transcrip-
tion and proviral integration event.
We cloned an approximately 200 bp Nef fragment into
the multiple cloning site (MCS) of the lentiviral vector
genome (JS1-Nef). This sequence contains the target
sequence for the potent shNef inhibitor that we described
in earlier studies [24,29]. As a control, we constructed a
vector with a mutant Nef sequence (JS1-R2), lacking 11
nucleotides of the shNef target sequence, which was
shown to be completely resistant to shNef attack [24,29].
During lentiviral vector production, the vector genome is
transcribed and transported to the cytoplasm where it
becomes packaged in the vector particle (Fig. 2a). When
the JS1-Nef lentiviral particles were produced in the pres-
ence of the shNef expression plasmid in the transfection
mix, we observed a significant reduction in titer (Fig. 2b).
In contrast, the titer of JS1 and JS-R2 vectors was similar to
their titer produced in the absence of shNef. This result
shows that the vector genome is in principle an effective
target for RNA interference.
The lentiviral vectors JS1, JS1-Nef and JS1-R2 were pro-
duced and subsequently used to infect the SupT1 T cell
line that stably expresses shNef [24] and control SupT1
cells. When the incoming RNA genome is targeted by
shRNA induced RNAi, the number of cells that obtain an
integrated proviral DNA copy should be reduced. This will
be reflected in a reduced transduction efficiency of shNef
cells compared to the control SupT1 cells (Fig. 3a). Two
days after infection, the cells were analyzed by FACS anal-
ysis. We did not observe a significant difference in the
transduction efficiency of JS1-Nef in the control cells ver-
sus shNef-expressing cells, indicating that the incoming
vector genome was not targeted by RNAi (Fig. 3b). Results
were similar for the empty vector JS1 and control vector
JS1-R2 with a deletion in the shNef target sequence. The
results were independent of the m.o.i., which ranged fromRetrovirology 2006, 3:57 http://www.retrovirology.com/content/3/1/57
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0.03 to 1. These combined results clearly indicate that the
incoming lentiviral RNA genome is not a target for RNAi.
As an additional control for the presence of a functional
shNef in the shNef-expressing SupT1 cells, we transfected
the luciferase reporter constructs [29] containing the com-
plete (pGL3-Nef) or mutant (pGL3-R2) target sequence
(Fig. 4a). Luciferase expression of pGL3-Nef was reduced
to 20% in the shNef-expressing cells compared to the con-
trol cells (Fig. 4b). In contrast, luciferase expression of
pGL3-R2 is similar in both cells. This confirms that SupT1
cells expressing shNef induce sequence-specific inhibition
of RNAs containing the Nef target sequence.
The lentiviral particles used in the experiments described
above are pseudotyped with the VSV-G envelope. One
could argue that VSV-G mediated entry and subsequent
intracellular processes are different from wildtype HIV-1
virions that contain the HIV-1 Envelope protein. The use
of VSV-G would thus explain why we do not observe tar-
geting of the incoming genome. To exclude this possibil-
ity, we produced lentiviral vectors with an HIV-1 Envelope
and repeated the experiment. Infection of SupT1 cells
expressing shNef with JS1-Nef lentivirus containing HIV-
1 envelope was similar to that of control SupT1 cells,
which demonstrates that the mode of entry does not con-
tribute to the absence of incoming genome targeting (Fig.
5).
The contradicting results in literature on inhibition of the
incoming HIV-1 RNA genome by RNAi may be due to dif-
ferences in experimental conditions. In fact, most studies
used chemically synthesized siRNAs that were transfected
into various cell types prior to challenge with HIV-1. We
therefore tested a synthetic siRNA directed against the
same shNef target. This siNef is the same as the one shown
The lentiviral vector and packaging constructs Figure 1
The lentiviral vector and packaging constructs. The lentiviral vector JS1 is a third generation self-inactivating vector [39], 
which contains a GFP reporter gene expressed from the phosphoglycate kinase promoter (PGK) with the posttranscriptional 
regulatory element (pre) from hepatitis B virus. The vector genome is expressed from the Rous sarcoma promoter (RSV) and 
transcription starts with the R and U5 regions of the HIV-1 long terminal repeat (LTR), the packaging signal (ψ) and part of the 
gag open reading frame (gag). It contains the rev responsive element (RRE), central polypurine tract (cPPT) and the 3' LTR, 
which has a deletion in the U3 region (∆U3). The HIV-1 sequences are tinted gray. Transcription of the vector genome and 
GFP reporter terminates at the HIV-1 polyA within the 3'LTR. The Nef target sequence (wild type or mutant) was cloned into 
the multiple cloning site (MCS). The three packaging constructs encode the trans-acting proteins required for the production 
of infectious virus (HIV-1 sequences in gray).
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by Jacque et al. to affect the level of integrated provirus
[12]. Cells transfected with siNef or a shNef expression
plasmid reduced pGL3 Luciferase Nef reporter expression,
when the reporter was transfected 24 hours post si or
shRNA transfection (Fig. 6b). In contrast, when these
siRNA or shRNA-expressing cells were infected with JS1-
Nef lentiviral particles, no drop in transduction efficiency
was observed compared to mock (-) or pBS-transfected
cells (Fig. 6c). Similar results were obtained with a range
of m.o.i. (results not shown). Thus, an active siRNA is also
unable to inhibit the incoming RNA genome.
In literature, a variety of different targets have been used
and variation in target accessibility in the context of the
packaged RNA genome may explain the contradicting
results. Our lab has constructed multiple potent shRNAs
against conserved regions in the HIV-1 RNA genome (ter
Brake, Mol. Ther., in press). Some of these shRNAs also
target the lentiviral vector genome (Fig. 6a; LDR9, Pol29
and Nef19). We transfected 293T cells with the different
shRNA-expression constructs and 24 hours later with the
appropriate reporter constructs. Alternatively, we infected
these cells after 24 hours with JS1-wtNef lentiviral vector.
The 3 additional shRNAs demonstrated full inhibitory
activity on the luciferase reporters (Fig. 6b; right 3 panels),
but lacked any activity on the incoming RNA genome (Fig.
6c), with one notable exception: shNef19 is an effective
inhibitor in both systems. The explanation for this excep-
tion comes from inspection of its target in the lentiviral
vector genome (Fig. 6a), which is actually located in the
3'LTR region, and thus part of the GFP transcript. The
observed drop in GFP-expressing cells is therefore caused
by direct RNAi-inhibition of the reporter transcript, and
not by targeting of the incoming RNA genome.
Discussion
We have not observed RNAi-mediated targeting of the
HIV-1 RNA genome of incoming particles using our lenti-
viral vector transduction system. The human T cell line
that stably expresses shRNAs directed against the viral Nef
gene shows effective inhibition of HIV-1 replication [24].
However, we could not demonstrate an effect on the level
of transduction with lentiviral particles, pseudotyped
either with VSV-G or wildtype HIV-1 envelope. Similar
results were obtained in a cell line transiently transfected
with an shNef-expressing plasmid prior to infection. The
intracellular levels of shRNAs is much higher upon trans-
fection than in stable cell lines (results not shown), but
even this increased concentration did not seem to affect
the transduction efficiency. In addition, we failed to
obtain an inhibitory effect on the incoming RNA genome
with other shRNAs that target different parts of the HIV-1
RNA genome or after transfection of a synthetic siRNA
against Nef. All these results strongly indicate that the
incoming HIV-1 RNA genome is not a target for RNAi.
The contradicting results that have been reported in liter-
ature may be due to differences in experimental condi-
tions. It has been claimed that differences in target
accessibility of different regions of the packaged RNA
genome contribute to the variation in experimental
Sequence-specific inhibition of lentiviral production by RNAi Figure 2
Sequence-specific inhibition of lentiviral production 
by RNAi. a) Schematic of lentiviral production. When an 
shNef-expression plasmid is co-transfected during lentiviral 
vector production, the lentiviral vector RNA genome con-
taining the Nef target (gray box) can be targeted by RNAi 
(dark arrow). b) Lentiviral vector stocks (JS1, JS1-Nef and 
JS1-R2) were produced in 293T cells in the absence (-shNef) 
or presence (+shNef) of an shNef-expression plasmid and 
were titrated on SupT1 cells. Transduced cells were analyzed 
by GFP-FACS. The mean values of three independent experi-
ments are shown. The control values (-shNef) were set at 
100% for each lentiviral vector.
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No sequence-specific inhibition of lentiviral transduction by RNAi Figure 3
No sequence-specific inhibition of lentiviral transduction by RNAi. a) Schematic of lentiviral transduction. When 
shNef is stably produced in the target cells, the question is whether the incoming vector genome with the shNef target 
sequence is targeted by RNAi (dark arrow with question mark). b) SupT1 cells stably expressing shNef (+ shNef) or control 
SupT1 cells (- shNef) were transduced at an m.o.i. of 0.03, 0.3 or 1.0 with the control vector (JS1) or vectors containing a com-
plete (JS1-Nef) or mutated (JS1-R2) shNef target sequence. Infected cells were analyzed by GFP-FACS. The control values (- 
shNef) were set at 100% for each lentiviral vector. The mean values of three experiments are shown.
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results, but we detected a lack of inhibition with a range
of targets, which are all highly accessible for RNAi-medi-
ated inhibition in the context of reporter constructs. Fur-
thermore, we demonstrated efficient targeting of the HIV-
1 RNA genome in the producer cell, before it is encapsi-
dated in the virion particle. It has been reported that the
cellular environment can affect both the efficiency and the
specificity of siRNAs and shRNAs [35]. The use of different
cell types can influence the observed RNAi effect. Addi-
tionally, the use of different promoters in shRNA expres-
sion plasmids might also influence the potency of
inhibition [36]. In addition, "nude siRNAs", not associ-
ated with RISC, may be able to enter the viral core when
present at high concentrations. Subsequent binding to the
viral RNA genome can induce antisense-mediated inhibi-
tion of reverse transcription, but not an RNAi effect.
An explanation for the absence of targeting of the incom-
ing viral RNA genome is inaccessibility to the RNAi
machinery. After fusion of viral particles with the target
cell membrane, the virion core is released into the cyto-
plasm. This coneshaped core consists of the capsid (CA-
p24) protein containing the RNA genome and viral
enzymes. This core is dissolved only partially during the
infection process. Furthermore, when the reverse tran-
scription complex (RTC) is formed, the genomic RNA is
still associated with multiple proteins (nucleocapsid
[NC], reverse transcriptase [RT], matrix protein [MA] and
integrase [IN]). The limited knowledge about the structure
of intracellular retroviral complexes prohibits a detailed
discussion, but there is supportive evidence that large
molecules cannot enter the core particle in which reverse
transcription occurs. For instance, it was shown that tRNA
molecules can enter the core particle in virus-infected
cells, but with an efficiency that is 4 to 5 orders of magni-
tude lower than the tRNA packaging efficiency in virion-
assembling cells [37]. We made a similar observation with
RNAi targeting the vector genome. During lentiviral vector
production the RNA genome is an efficient target, result-
Sequence-specific inhibition in shNef-expressing cells Figure 4
Sequence-specific inhibition in shNef-expressing 
cells. a) Schematic of RNAi-mediated targeting of mRNA 
with the shNef target sequence (gray box) in shNef-express-
ing SupT1 cells. b) SupT1 cells stably expressing shNef (+ 
shNef) or control SupT1 cells (- shNef) were transfected 
with luciferase reporter constructs that contain the com-
plete shNef target sequence (pGL3-Nef) or not (pGL3-R2). 
The mean values obtained in two independent experiments 
are shown. Values measured in the control transfection (- 
shNef) were set at 100% for each reporter construct.
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ing in reduced titers. In contrast, RNAi directed against the
incoming genome could not reduce the transduction effi-
ciency. Given the size of the RISC complex, it is likely that
RISC cannot enter the viral particle, thereby explaining
our results.
Conclusion
Using lentiviral vector transduction as a model for HIV-1
infection, we have shown that the incoming HIV-1
genome cannot be targeted directly by RNAi. For effective
gene therapy applications based on RNAi, it would be
beneficial to target the incoming virus, thus blocking pro-
virus establishment and in fact new infection of cells. To
achieve this objective, one should target cellular receptors
or co-factors that are involved in the initial phase of infec-
tion [15,38].
Methods
Plasmid construction
Lentiviral vector plasmids are derived from the construct
pRRLcpptpgkgfppreSsin [39], which we renamed JS1. The
plasmids JS1-Nef and JS1-R2 were obtained by digestion
of the firefly luciferase expression vectors pGL3-Nef and
pGL3-R2, containing an ~250-bp Nef fragment down-
stream of the luciferase gene [29], with XhoI and PstI and
inserting this fragment into the corresponding sites of JS1.
The other firefly reporter plasmids (pGL3-LDR9 and -
Pol29 and -Nef19) were constructed by insertion of a 50–
70 nucleotide HIV-1 sequence, with the 19-nucleotide tar-
get in the center, in the EcoRI and PstI sites of pGL3-Nef
(ter Brake et al.; in press).
The pSUPER vector [8], which contains the H1 polymer-
ase III promoter, was linearized with BglII and HindIII.
Sense and antisense strand oligonucleotides, which
encode the shRNA sequence against a conserved 19-nucle-
otide HIV-1 region (LDR9; AGATGGGTGCGAGAGCGTC
[798], Pol29; CAGTGCAGGGGAAAGAATA [4811] and
Nef19; GGGACTGGAAGGGCTAATT [9081] ter Brake et
al.; in press) or the Nef [24] sequence, were annealed and
ligated into pSUPER. The number between the brackets
indicates the nucleotide position in prototype HIV-1
strain HXB2. The plasmid pRL-CMV (Promega) expresses
Renilla luciferase under control of the CMV promoter.
Cell culture
Human embryonic kidney (HEK) 293T adherent cells
were grown at 37°C and 5% CO2 in DMEM (Gibco BRL)
and SupT1 suspension cells were grown in RPMI 1640
(Gibco BRL), both supplemented with 10% Fetal Calf
Serum (FCS), penicillin (100U/m) and streptomycin (100
µg/ml). The SupT1 cells stably expressing shNef were
described previously [24].
Lentiviral vector production
293T cells were grown to 50% confluence in 2 ml culture
medium in 9.4 cm2 wells. The medium was replaced with
No inhibition of lentiviral transduction in cells transfected  with different shRNA plasmids or siRNA Figure 6
No inhibition of lentiviral transduction in cells trans-
fected with different shRNA plasmids or siRNA. a) 
Map of the JS1-Nef genome with the positions targeted by 
the shRNA inhibitors. b) 293T cells were mock transfected 
(-) or transfected with siNef or plasmids expressing the indi-
cated shRNAs. The cells were subsequently transfected with 
luciferase reporter constructs containing the target 
sequences and relative luciferase expression was measured. 
The mean values obtained in two independent experiments 
are shown. The control value (-) was set at 100% for each 
luciferase reporter. c) 293T cells were mock transfected (-) 
or transfected with the control pBS, siNef or plasmids 
expressing the indicated shRNA. The cells were subsequently 
transduced with the JS1-Nef vector. Transduction efficiency 
was determined by GFP-FACS. The mean values obtained in 
two independent experiments are shown. The transduction 
efficiency for the control experiment (-) was set at 100%.
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2 ml medium without antibiotics. Subsequently, the len-
tiviral vector plasmid (2.2 µg) was co-transfected with
packaging plasmids pMDLg/pREV (1.45 µg), RSV-REV
(0.56 µg), and pVSV-G (0.78 µg) [40,41] or the pSV7D
plasmid encoding HXB2 gp160 (0.78 µg). The pSV7D
Envelope gp160 plasmid was a kind gift of Dr. J. Binley
(Torrey Pines Institute for Molecular Sciences, La Jolla,
CA, USA). Co-transfection in 3 ml was performed with 5
µl lipofectamine-2000 and 0.5 ml Optimem (Gibco BRL).
The culture medium was refreshed after 16 hrs. Medium
containing the lentiviral vector was harvested the next day
and replaced with fresh medium. This procedure was
repeated after 24 hrs. The supernatants were mixed, cellu-
lar debris was removed by low speed centrifugation and
aliquots of 0.5 ml were stored at -80°C. For lentiviral vec-
tors produced with HIV-1 envelope, the stocks were con-
centrated with an Amicon Ultra concentrator, MWCO
100,000 (Millipore Corporation, Bedford, MA, USA).
Lentiviral vector transduction
Lentiviral vector stocks were titrated on 293T cells and
SupT1 cells. SupT1 (1.0 × 105 cells in 0.5 ml medium) and
293T (1.0 × 105 cells in 0.5 ml medium) were subse-
quently transduced at various m.o.i. (from 0.01 to 1). Two
days after transduction the cells were harvested, fixated in
4% paraformaldehyde and analysed by FACS for GFP
expression (FACScan, BD Biosciences).
Transfection experiments
293T cells (2 cm2; 1.0 × 105 cells) were seeded in 500 µl
DMEM with 10% FCS without antibiotics. The next day, 1
µg pSUPER-shRNA plasmid, 125 nM siRNA or 1 µg con-
trol pBS (pBluescriptII (KS+); Stratagene) was transfected
with 1 µl lipofectamine-2000 in a reaction volume of 100
µl according to the manufacturers instructions (Invitro-
gen). Sixteen hrs post-transfection the medium was
replaced with 500 µl medium with antibiotics, and the
cells were subsequently used for transduction or luciferase
experiments.
For luciferase experiments, 293T cells (2 cm2; 60% conflu-
ent) were transfected with 200 ng pGL3-constructs and 1
ng pRL using lipofectamine-2000. SupT1 cells (shNef-
expressing and control) were transfected with luciferase
plasmids by electroporation. Briefly, 5 × 106 cells were
washed in RPMI 1640 medium with 20% FCS and mixed
with 5 µg pGL3-constructs and 150 ng pRL in 250 µl of
RPMI 1640 medium with 20% FCS. Cells were electropo-
rated in 0.4 cm cuvettes at 250 V and 975 µF and subse-
quently resuspended in RPMI 1640 medium with 10%
FCS. The culture medium was refreshed after 16 h. After
another 24 h, the cells were lysed in 150 ml of Passive
Lysis Buffer (PLB) (Promega). Firefly and renilla luciferase
activities in the lysate were measured with the Dual-luci-
ferase Reporter Assay System (Promega).
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